Awardee OrganizationBOSTON UNIVERSITY MEDICAL CAMPUS
Description
Abstract Text
Bone morphogenetic proteins (BMPs) are potent morphogens that have been shown to promote chondrogenic and osteogenic differentiation. This has been demonstrated in vitro, within model systems of mesenchymal stem cells, and in vivo when recombinant BMPs have been implanted or injected into ectopic, heterotopic or orthotopic sites. BMPs are also expressed at elevated levels throughout all stages of bone repair and have been shown, when exogenously administered, to enhance the healing response. Hypothesis: BMPs are critical in the regulation of all phases of fracture healing. In order to test this hypothesis, the studies proposed in this application will generate transgenic mice in which a novel experimental strategy is employed
that restricts the expression of a transgene to either cartilage or bone and allows for the exogenous regulation of that transgene through systemic administration of a small molecule. Transgenic animals will be engineered to contain an artificial transcription factor encoded in two proteins, a novel DNA binding domain and an activation domain. The expression of these domains will be driven by a tissue-specific promoter (type II collagen for cartilage or osteocalcin for bone). The transcription factor will be activated by the exogenous administration of a dimerizing agent (rapamycin analog), which brings these domains into proximity. When activated, it will recognize a unique promoter which will drive the overexpression of BMP-2 or antagonize
BMP function by overexpressing Noggin. Using this strategy, transgenic animals will undergo normal embryological development and fractures (or, in the case of Project 1, distraction osteogensis) will be carried out in the presence of normal skeletal function. Only upon introduction of the dimerizing agent will loss or gain of function states be induced through the overexpression of these transgenes. Fracture healing will then be analyzed in specific tissues and at specific times under conditions in which BMP function is altered. These studies will provide extensive new data concerning the specific roles that BMPs play at critical stages
of fracture healing and establish a powerful model system for investigating a wide array of molecules and their effects on skeletal function.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
Biological ModelsBiomechanicsBone Morphogenetic ProteinsBone RegenerationBone TissueBone and Cartilage FundingBone callusBone remodelingCCI-779CalcifiedCartilageCell LineCellsChondrogenesisCollagen Type IIConditionDNADNA Binding DomainDataDevelopmentEngineeringExtracellular MatrixFractureFracture HealingHealedImplantIn VitroLaboratoriesMesenchymal Stem CellsMethodsMolecularMusOsteocalcinPhasePhysiologic OssificationPhysiologic calcificationPlayProductionPropertyProtein OverexpressionProteinsRecombinantsRecruitment ActivityRegulationRoleSiteSkeletal systemSpecificityStagingStandards of Weights and MeasuresSystemTestingTimeTissuesTranscriptional ActivationTransgenesTransgenic AnimalsTransgenic Miceangiogenesisbonebone morphogenetic protein 2daydistractiongain of functionhealingin vivomorphogensnovelpromoterprotein functionrepairedresponsesmall moleculestoichiometrytibiatranscription factortransgene expression
National Institute of Arthritis and Musculoskeletal and Skin Diseases
CFDA Code
DUNS Number
604483045
UEI
FBYMGMHW4X95
Project Start Date
01-June-2007
Project End Date
31-May-2009
Budget Start Date
01-June-2007
Budget End Date
31-May-2008
Project Funding Information for 2007
Total Funding
$271,033
Direct Costs
$169,576
Indirect Costs
$101,457
Year
Funding IC
FY Total Cost by IC
2007
National Institute of Arthritis and Musculoskeletal and Skin Diseases
$271,033
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5P01AR049920-04 0002
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P01AR049920-04 0002
Patents
No Patents information available for 5P01AR049920-04 0002
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P01AR049920-04 0002
Clinical Studies
No Clinical Studies information available for 5P01AR049920-04 0002
News and More
Related News Releases
No news release information available for 5P01AR049920-04 0002
History
No Historical information available for 5P01AR049920-04 0002
Similar Projects
No Similar Projects information available for 5P01AR049920-04 0002